Why your doctor brushed off your menopause symptoms.

Over the weekend I talked with a woman who told me she has a partial blockage in one of her coronary arteries. She has known about it for years.

She is also in the middle of menopause symptoms that are taking apart her sleep, her focus, and most of her day.

She asked her doctor about hormone therapy for the symptoms. She told me the answer was no, because estrogen causes blood clots.

I only have her side of it, and I was not in the room. What she came away with was a no and not much else. She did not know which kind of clot was meant, or whether the delivery route changed anything, or what else might still be on the table.

She walked out with the same symptoms she walked in with.

I have no way to evaluate her heart and I would not try. Whether hormone therapy is right for her is a question for her physician and her cardiologist, and a no may well be the correct answer.

What I keep turning over is the shape of the conversation, not the verdict. A no that comes with an explanation gives a woman somewhere to go next. A no with nothing attached to it gives her nowhere, and she is the one who has to live in the body.

How often does this actually happen?

Often enough that it shows up every time somebody measures it, though the measurements are messier than the headlines suggest.

The most detailed peer-reviewed account I found is the Women Living Better survey, published in the Journal of Women's Health in 2023. It asked 2,406 women about perimenopause. Among those who described going to a provider, 49 percent called the interaction negative. 18 percent called it positive.

The theme the researchers pulled out was invalidation. Being told they were too young. Being told that regular cycles meant it could not be perimenopause. Being brushed off.

Worth knowing what that number is and is not. It is a self-selected online sample, 85 percent white and 81 percent college-educated, and the authors say plainly that it cannot tell you how often this happens in the general population. It tells you what these appointments look like when they go badly. Not how common that is.

For frequency, Gallup surveyed 3,845 women in July 2026. 34 percent said a provider has minimized or dismissed their symptoms. For men it was 21 percent. Among the women who specifically sought treatment for menopause or perimenopause symptoms, 24 percent said they had to push to be taken seriously and 23 percent had to see multiple providers before anything was addressed.

In the UK, the Fawcett Society surveyed more than 4,000 women. 31 percent said it took many appointments before a GP recognized what was happening. That one was commissioned for a television documentary rather than peer-reviewed, so hold it loosely.

An AARP analysis of national expenditure data comes at it from a different direction and is starker. Only about 5 percent of US women aged 45 to 64 received any treatment for menopause in 2021. That works out to roughly 20 to 25 percent of the women actually going through it.

Different groups, different methods, 2 countries. They are not all measuring the same thing, since one is a treatment rate and the rest are self-reported experience. The numbers keep landing in the same place anyway.

Nobody taught them

In 2022, researchers surveyed the directors of US OB/GYN residency programs. 145 programs were invited and 99 responded, a 68 percent response rate, which is strong for this kind of survey.

• 31.3 percent of responding programs had any menopause curriculum.
• Of those that did, 71 percent offered 2 or fewer lectures per year.
• 29.3 percent had designated time in a menopause clinic.
• Asked how prepared their own residents were, directors gave an average score of 3.83 out of 10.

One honest caveat. There are somewhere around 270 to 300 accredited OB/GYN residency programs in the US, so 145 invitations and 99 replies is a partial picture. Nothing is known about the programs that were never asked.

A 2019 study in Mayo Clinic Proceedings asked the residents themselves, across family medicine, internal medicine and OB/GYN at 20 programs. 6.8 percent felt adequately prepared to manage menopausal women. 20.3 percent had received no menopause lectures during residency. And 34.4 percent said they would not offer hormone therapy to a newly menopausal woman with bothersome symptoms and no contraindications.

That last number is worth sitting with. A third of residents would decline in the textbook case, the one where the guidelines are least ambiguous.

The response rate on that study was 26 percent, which is low. The residents who bothered to answer were probably the ones who cared most about the topic. If anything that biases the numbers toward looking better than reality.

I want to be fair about what this shows. It is not evidence that doctors do not care. In the residency director survey, 92.9 percent agreed residents should have a standardized menopause curriculum. 83.8 percent said they needed more resources to teach it. They know.

So when a woman gets 10 minutes and a shrug, she is often meeting the edge of what that clinician was ever given.

The part that gets routed to psychiatry

One version of this comes up constantly.

Perimenopause and menopause produce symptoms that look, on a quick read, like standalone mental health conditions. Anxiety that arrived out of nowhere. Sleep that breaks at 3am. Mood shifts. Word-finding trouble and the brain fog that scares women more than anything else on the list.

A LifeStance survey of 1,000 US women who have or suspect perimenopause, fielded in late June and published in August, asked what they thought was going on before they understood it. 49 percent thought they had anxiety. 39 percent suspected depression. 36 percent said they were surprised to learn that perimenopause symptoms can present as a mental health condition on their own.

That survey was commissioned by a mental health company, which has an obvious interest in the finding. The direction still matches everything else.

The statistic that circulates hardest here is that 39 percent of women were offered antidepressants instead of hormone therapy as a first option. I want to be straight about where that comes from: a self-selected online survey of UK women run by a commercial menopause clinic. It is not peer-reviewed and it is not American. I could not find a verified US equivalent, which is its own small scandal.

A study published in JAMA Network Open in July compared 577 posts from an online menopause community against 646 clinical notes, drawn from a screen of more than 2 million records at a large health system. Cognitive impairment showed up in about 20 percent of the online posts and about 5 percent of the clinic visits.

The symptoms are getting described. They are getting described on Reddit instead of to a doctor.

Who gets dismissed the most

Not evenly distributed.

In the Fawcett Society data, 45 percent of Black and minoritized women said it took many appointments to be recognized, against 30 percent of white women.

The AARP treatment numbers split the same way. In 2021, 6.3 percent of non-Hispanic white women aged 45 to 64 were treated for menopause. For Hispanic women it was 2.7 percent. For non-Hispanic Black women, 2.5 percent.

What does a bad appointment actually cost?

Mayo Clinic surveyed 4,440 employed women aged 45 to 60. 13.4 percent reported an adverse work outcome they attributed to menopause symptoms. Women in the most symptomatic quartile were 15.6 times more likely to have one.

The researchers put the lost work time at roughly 1.8 billion dollars a year in the US. That study had a 16 percent response rate and a mostly white sample from one health system, so treat the dollar figure as an order of magnitude rather than a measurement.

The direction is not really in doubt, though. When a woman is told this is just aging and sent home, that shows up in her job, her sleep, her marriage, and her willingness to ever raise it again.

That is what a bad 10 minutes costs. The next time something is wrong, she waits longer to say so.

"It will not help your heart" and "it could hurt your heart" are different sentences

This is the part I most want to separate out, because three different claims get welded into one word and that word is usually just "no."

Claim one: estrogen does not prevent heart disease. This is true and well supported. Every major guideline says hormone therapy should not be used for cardiovascular prevention, including the permissive European ones.

But look at what that sentence is actually about. It is about using estrogen as a heart drug. On its own it says nothing about whether a woman can take it for hot flashes. If "it will not help your heart" were the whole basis for a no, that would be an answer to a question nobody asked.

Claim two: in women who already have coronary disease, there is a harm signal. This is the real basis for the caution, and it is a different finding.

In the HERS trial, published in 1998, 2,763 women with established coronary disease were given oral conjugated estrogen plus a synthetic progestin. In year one there were more cardiac events in the treatment group than in placebo. Not an absence of benefit. More events.

Claim three: estrogen affects clot risk. Separate again, and it depends heavily on how the estrogen gets into the body. More on that below.

Those three get collapsed constantly, including in a lot of writing about this. They should not be.

How strong is that harm signal, honestly?

Narrower than the flat contraindication language suggests, which is exactly why the guidelines do not agree with each other.

• In HERS, the excess was in year one only. Event rates were comparable between the groups for the remainder of the follow-up, which averaged 6.8 years.
• The ERA trial, published in 2000 in women with angiographically documented coronary disease, found that estrogen neither slowed nor accelerated the progression of their disease on imaging.
• A 2024 systematic review in Climacteric pooled 29 studies of hormone therapy in women with cardiovascular disease. It found no significant difference in non-fatal heart attack, cardiovascular death, or stroke between users and controls. No benefit, and no demonstrated harm either.
• All of the foundational data used oral conjugated equine estrogen plus a synthetic progestin, in women averaging 66.7 years old. That is a different intervention in a different population than transdermal estradiol in a woman in her early 50s.

So: one early signal, in one trial, with a formulation and a population that do not match how this would be prescribed today, and nothing since has confirmed it.

That is a defensible reason for caution. In my reading it is not a settled one. And it is not the same claim as "estrogen will not help your heart."

Where the guidelines stop agreeing

Here is where I want to be careful, because this is a medical decision and it belongs to a woman and her physician.

What I can tell you is what the published guidance says. It is less unanimous than a flat no suggests, and most women are never told there is a conversation to be had.

Read the first two rows next to each other. The US label language names events: a heart attack, a stroke, a clot. The Menopause Society list is broader and includes prior coronary heart disease as a category.

Whether a particular cardiac finding sits inside that wording is a question for the physician holding the whole chart. It is not a question I can answer and not one a reader should try to answer from an article. But it is a real question, and in my view it is one a woman is entitled to hear answered out loud rather than summarized as a single word.

Three other things get left out of a blanket no often enough to be worth knowing about.

Venous and arterial are not the same problem

A clot in a vein and plaque in a coronary artery are different biology. The clot risk people usually mean is the venous kind, and in the research it depends a great deal on how the estrogen is delivered.

Oral estrogen passes through the liver first, which raises clotting factors. Transdermal largely skips that pass. In the French ESTHER study, oral estrogen carried an odds ratio of 4.2 for venous thromboembolism (95% CI 1.5 to 11.6). Transdermal came in at 0.9 (0.4 to 2.1), meaning no statistically detectable increase, in a study not large enough to rule out a modest one.

ACOG's committee opinion on this, reaffirmed in 2020, says clinicians "should take into consideration the possible thrombosis-sparing properties of transdermal forms."

That is a real distinction, and most women never hear it as two separate things.

Local vaginal estrogen is a separate question

This one I find genuinely frustrating, because it gets swept into the same no so often.

Low-dose vaginal estrogen, used for dryness, pain with sex, urinary urgency and recurrent UTIs, behaves differently from systemic therapy. When the FDA moved on hormone labeling, ACOG and The Menopause Society both backed removing the warning from low-dose vaginal products specifically. That held even where they stayed reserved about systemic products.

A retrospective analysis of 549,925 women in a large claims database, presented at a conference in 2024 and not yet published in a peer-reviewed journal, found no increase in major adverse cardiac events with vaginal estrogen. Among women who had already had a cardiac event, the rate was 23 percent with vaginal estrogen and 23 percent without.

If a meaningful share of what a woman is dealing with is genitourinary, that deserves its own conversation. Not a fold-in to a single answer about her heart.

Non-hormonal options that did not exist in 2020

Two new non-hormonal prescription drugs for moderate to severe hot flashes have been approved since 2023. Fezolinetant (Veozah) was approved in May 2023 and picked up a boxed warning for rare but serious liver injury in December 2024. Elinzanetant (Lynkuet) was approved on October 24, 2025.

Both work on the brain's temperature regulation rather than by replacing hormones. Neither one solves everything and both have tradeoffs to go over with a prescriber. But for a woman who cannot take estrogen, "there is nothing for you" is not accurate. Both are recent enough that they may not come up unless somebody asks.

What changed at the FDA, and what did not

You have probably seen headlines saying the warning came off hormone therapy. That is true and it is being oversold, so here is the careful version.

On November 10, 2025, HHS and the FDA requested that manufacturers remove the boxed warning language. On February 12, 2026, the FDA approved a first batch of revised labels covering 6 products across all 4 categories of menopausal hormone therapy. The rollout across the rest is still in progress.

What came off: the boxed warning covering cardiovascular disease, breast cancer and probable dementia, plus the old instruction to use the lowest dose for the shortest time.

What stayed: a history of heart attack or stroke is still an explicit contraindication on the revised labels. The cardiovascular data did not vanish either. It moved from the boxed warning into the warnings and precautions section.

Also worth knowing before taking the headline at face value. The Women's Health Initiative steering committee filed a response to the FDA panel saying some of the presentations were "inaccurate, misleading, or out of context." On the timing hypothesis, they wrote that the claim an early start's lower risk carries forward into later decades "remains untested." The Menopause Society endorsed the removal for low-dose vaginal estrogen and did not endorse it for systemic. ACOG said the change "does not change ACOG's guidance."

So the regulatory fear has been dialed down, which I think was overdue. The contraindications did not disappear. Anyone telling you hormone therapy is now simply safe is skipping as much as the people who spent 20 years telling you it was simply dangerous.

Both versions are shorter than the real answer.

Questions worth bringing with you

None of these require anyone to override anyone. They are the questions I would want answered before accepting a no, and they are phrased to be asked rather than argued.

• Which specific contraindication are you applying to me, and where does it come from?
• Is the concern about a prior cardiac event, or about a finding on a test? Does the guidance treat those the same way?
• Are you referring to venous clot risk or arterial disease risk? Are both concerns in my case?
• Does the route of delivery change your answer? Oral versus a patch or gel?
• Is low-dose vaginal estrogen a separate question from the systemic one for me?
• Are the newer non-hormonal prescription options for hot flashes appropriate for me?
• Can we get my cardiologist's input rather than deciding this inside one specialty?
• If the answer stays no, what is the plan for the symptoms? What do we do instead?
• Is there someone in the practice certified in menopause care?

That last one sounds rude. It is not. It is the same question you would ask before a knee surgery.

The Menopause Society keeps a public directory of certified practitioners. There are fewer than 4,500 of them against more than 49,000 OB-GYNs, so finding one nearby is not automatic. In my opinion it is still the highest-yield move available to a woman who is getting nowhere.

She was not asking anyone to gamble with her heart

She was asking what to do about her life. That question did not get an answer, and it is a different question from the one about her heart.

I do not think the fix here is women pushing harder, although plenty of them are going to have to. A training gap this size is not something a well-prepared patient closes on her own in a 12-minute appointment.

But knowing that the guidelines argue with each other is worth something in the room. It turns a flat no into a question about which no, and why. That is something a clinician can actually answer. In the conversations I have, that version tends to land better than a push.

This is one practitioner's opinion and a summary of public research. It is educational, not medical advice, and it is not a diagnosis or a recommendation for or against any therapy. Decisions about hormone therapy, cardiac care and prescription medication belong with a licensed physician who knows your history. The Integrative Wellness practice works alongside your medical team, not in place of one. Nothing here should be used to start, stop or change a medication without your prescriber's involvement. Guideline positions summarized above are paraphrased and current as of September 2026; the primary documents are linked below and should be read directly for exact language.